1 completed, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Urothelial Carcinoma of the Bladder: new trials by email Literature Review of Urothelial Carcinoma of the Bladder trials Research Report on Urothelial Carcinoma of the Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AN0025 and Pembrolizumab Combination in Advanced Solid Tumors AN0025, Pembrolizumab - Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous | Phase 1 | Unknown | Adlai Nortye Biopharma Co., Ltd. | 63 | 2020-08-20 | 2024-06-27 |
| Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer Proton therapy, IMRT - Urothelial Carcinoma of the Bladder | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 2 | 2012-01-01 | 2019-11-26 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Spinocerebellar Degenerations (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Brain Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Cerebellar Diseases (1) · Colonic Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
E7046 (1) · Proton Therapy (1) · pembrolizumab (1)
Abramson Cancer Center at Penn Medicine (1) · Adlai Nortye Biopharma Co., Ltd. (1)
United States (2) · France (1)
John Christodouleas, MD (1) · Robert Atkinson, Ph.D. (1)
2019 (1)